Search

… highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial position with $50 …

… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas …

… and other DEB mutations An introduction to ProQR’s novel RNA editing platform technology called Axiomer LEIDEN, the …

… ProQR’s strategic focus on its proprietary Axiomer ®  RNA editing technology platform and continued advancement of …

… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … to progress its other pipeline candidates, to advance its RNA-editing technology platforms, and for working capital and …

… bring a tremendous amount of experience in the fields of RNA-based therapeutics and genetic pediatric diseases. The … of the Company’s novel and proprietary next generation RNA editing technology, Axiomer®, that utilizes endogenous …

… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual …

… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” Business Operations and … ®  EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change …